Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2017-09-07 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC AND ABIVAX ENTER INTO STRATEGIC COLLABORATION TO DEVELOP NOVEL ANTIVIRAL AGENTS
Regulatory Filings Classification · 100% confidence The document is a press release dated September 7, 2017, announcing a strategic collaboration between Evotec AG and ABIVAX to develop novel antiviral agents. It details the terms of the partnership, the scientific focus (RSV, Influenza, Dengue), and includes quotes from management. This type of announcement, detailing a significant business development like a strategic alliance or partnership, does not fit the specific definitions for 10-K, ER, IR, or AGM materials. It is a corporate news item concerning business operations and potential future value creation. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or Major Shareholding (MRQ), and it is not a transcript (CT) or a presentation (IP), the most appropriate general category for a significant, non-standard corporate announcement that isn't explicitly covered elsewhere is the fallback category, Regulatory Filings (RNS), which often serves as a catch-all for press releases about strategic deals disseminated via services like DGAP.
2017-09-07 English
EVOTEC TO ATTEND UPCOMING INVESTOR CONFERENCES
Report Publication Announcement Classification · 99% confidence The document is a press release dated September 6, 2017, announcing that Evotec AG management will be presenting at several upcoming investor conferences (Morgan Stanley, Goldman Sachs, Bank of America Merrill Lynch, etc.) and listing the dates, locations, and attending executives for each event. This content directly relates to investor relations activities and scheduled presentations to the investment community, which aligns best with the Investor Presentation (IP) category, although it is an announcement *about* presentations rather than the presentation slides themselves. However, given the options, this type of announcement detailing management's schedule for engaging investors at conferences is most closely related to investor outreach materials. Since it is an announcement of future events rather than a formal regulatory filing (like 10-K, AR, or ER), and it specifically details investor engagement, 'Investor Presentation (IP)' is the most fitting category among the choices, as it signals upcoming investor-facing material or the schedule for such engagement. It is not a general regulatory filing (RNS) because it is highly specific to investor events.
2017-09-06 English
DGAP-DD: Evotec AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a 'person discharging managerial responsibilities' (Dr. Mario Polywka, Member of the managing body). It follows the structure of a mandatory disclosure concerning insider transactions, specifically detailing the nature of the transaction (Exercise against Cash Settlement linked to share option programmes), price, volume, and date. This directly corresponds to the definition of Director's Dealing.
2017-09-05 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Evotec AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of 31.08.2017. It details a 'Type of capital measure' related to a 'Conditional capital increase' and provides the 'New total number of voting rights'. This type of announcement, which reports on changes to the total number of shares/voting rights, is most closely aligned with capital structure changes or regulatory notifications regarding share counts. While it relates to capital, the specific nature of reporting the total voting rights count based on German securities law (WpHG Article 26a) makes it a specific regulatory disclosure. Given the options, 'Share Issue/Capital Change' (SHA) covers changes in capital structure, but 'Declaration of Voting Results & Voting Rights Announcements' (DVA) specifically covers voting rights announcements. Since this is a formal announcement of the total voting rights count, DVA is the most precise fit, although SHA is also relevant. However, DVA is defined as 'Official results from shareholder votes at any general meeting (AGM or EGM)' which this is not; it's a statutory disclosure of the total count. Since it is a mandatory regulatory disclosure concerning the capital structure (voting rights), and it doesn't fit perfectly into the other specific categories like DIV or CAP, it falls under the general regulatory announcement category, RNS, or potentially SHA if interpreted broadly as a capital structure update. Given the focus on 'Total Voting Rights Announcement' and the regulatory context (WpHG), it is a specific regulatory filing. Since there isn't a perfect 'Voting Rights Disclosure' code, and it is a mandatory regulatory release, RNS (Regulatory Filings) is the appropriate fallback for specific regulatory disclosures not covered elsewhere. However, since it explicitly details a capital measure ('Conditional capital increase'), SHA (Share Issue/Capital Change) is also a strong candidate. I will choose SHA as the core subject is the resulting total share count from a capital action, even if the announcement format is regulatory.
2017-08-31 English
DGAP-DD: Evotec AG english
Director's Dealing Classification · 100% confidence The document explicitly contains the header 'Directors’ Dealings' and the title 'DGAP-DD: Evotec AG english' followed by 'Notification and public disclosure of transactions by persons discharging managerial responsibilities...'. This content directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2017-08-24 English
DGAP-DD: Evotec AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains detailed information regarding a transaction by a person discharging managerial responsibilities ('Dr. Werner Lanthaler, Member of the managing body'). It follows the structure of a mandatory disclosure concerning insider transactions, specifically detailing the nature of the transaction ('Purchase of shares by exercising stock options'), the price, volume, and date. This directly corresponds to the definition of Director's Dealing.
2017-08-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.